Gilead Sciences, Inc. (GILD)
- Previous Close
83.90 - Open
83.26 - Bid 78.85 x 100
- Ask 87.45 x 100
- Day's Range
82.75 - 83.99 - 52 Week Range
62.07 - 87.87 - Volume
24,672,671 - Avg. Volume
6,673,338 - Market Cap (intraday)
104.504B - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
102.37 - EPS (TTM)
0.82 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield 3.08 (3.67%)
- Ex-Dividend Date Sep 13, 2024
- 1y Target Est
82.33
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
www.gilead.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GILD
View MorePerformance Overview: GILD
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GILD
View MoreValuation Measures
Market Cap
104.50B
Enterprise Value
125.08B
Trailing P/E
102.37
Forward P/E
11.71
PEG Ratio (5yr expected)
0.50
Price/Sales (ttm)
3.78
Price/Book (mrq)
5.72
Enterprise Value/Revenue
4.50
Enterprise Value/EBITDA
23.73
Financial Highlights
Profitability and Income Statement
Profit Margin
3.79%
Return on Assets (ttm)
11.55%
Return on Equity (ttm)
5.26%
Revenue (ttm)
27.8B
Net Income Avi to Common (ttm)
1.05B
Diluted EPS (ttm)
0.82
Balance Sheet and Cash Flow
Total Cash (mrq)
3.78B
Total Debt/Equity (mrq)
128.32%
Levered Free Cash Flow (ttm)
6.79B